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Introduction 1
Approximately one third of the proteins encoded by the mammalian genome are 2 secretory proteins (1, 2). These proteins traffic from the endoplasmic reticulum (ER) to 3 the Golgi apparatus via coat protein complex II (COPII) vesicles before reaching their 4 final destinations: endosomes, lysosomes, plasma membrane, or extracellular space. 5 COPII vesicles have an inner coat composed of SAR1 and SEC23-SEC24 heterodimers 6 and an outer coat composed of SEC13-SEC31 heterotetramers (3). Though 7 transmembrane cargo proteins may directly interact with COPII components, the 8 physical barrier created by the ER membrane prevents direct interaction between 9 soluble cargos and the COPII coat. Therefore, soluble cargos either passively flow into 10 COPII vesicles (bulk flow) or are captured in COPII vesicles through recognition by 11 intermediary receptors or adaptors (cargo capture) (4). 12 Support for receptor-mediated cargo capture arose from early electron microscopy 13 studies and in vitro assays of cargo packaging in COPII vesicles, which demonstrated 14 efficient selection and concentration of cargos into COPII vesicles, as well as physical 15 interactions between soluble cargos and COPII components (4-9). Subsequent studies 16 uncovered LMAN1 as the first ER cargo receptor that mediates ER export of soluble 17 cargos in mammals (10-12). LMAN1, together with its adapter MCFD2, form a complex 18 that is required for the efficient secretion of coagulation factors V and VIII, cathepsins, 19 and alpha1-antitrypsin (12-16). While a handful of additional interactions between 20 soluble cargos and ER receptors have been described in mammals (4, 9, 17), the extent 21 to which bulk flow and cargo capture contribute to recruitment of proteins in COPII 22 vesicles is unclear. This is primarily due to the fact that ER cargo receptors that are 23 necessary for the efficient secretion of the majority of soluble cargos remain 1 unidentified. 2 Erythropoietin (EPO) is a glycoprotein that is produced predominantly by specialized 3 kidney peritubular fibroblasts and secreted into the plasma (18-21). EPO binds to its 4 receptor expressed on erythroid precursors and promotes cell survival, proliferation, 5 and differentiation (22) (23) (24) . EPO plays a crucial role in the regulation of red blood cell 6 production (erythropoiesis). Failure to make sufficient amounts of EPO, as seen in the 7 setting of chronic kidney disease, results in anemia. In contrast, supra-physiological 8 EPO levels, as seen in the context of EPO-secreting tumors, result in polycythemia. 9
Though the transcriptional regulation of EPO production has been well-studied (25-30), 10 the molecular basis of EPO trafficking remains poorly understood. 11
In this study, in an effort to identify proteins involved in EPO secretion, we developed a 12 genome-scale CRISPR/Cas9 knock-out screen that provides a quantifiable and 13 selectable readout of intracellular EPO levels. This screen, followed by several validation 14 experiments, identified the ER cargo receptor SURF4 as a key mediator of efficient EPO 15 secretion. These findings suggest that modulation of SURF4 in the EPO producing cells 16 could provide a novel strategy for altering plasma EPO levels and therefore regulating 17 erythropoiesis. Additionally, this report suggests a novel strategy for improving the 18 efficiency of recombinant EPO production. 19
Results: 1
Generation of a reporter cell line that allows for a quantifiable and 2 selectable readout of intracellular EPO levels 3
To identify proteins that regulate the intracellular trafficking of EPO, we developed a 4 genome-scale functional screen that provides a quantifiable and selectable readout of 5 intracellular EPO accumulation. Therefore, we generated a reporter HEK293T cell line 6 stably expressing eGFP-tagged EPO (EPO-eGFP) and, as an internal control, mCherry-7 tagged alpha1-antitrypsin (A1AT-mCherry) ( Fig. 1A ). This cell line is herein referred to 8 as the EPO-eGFP/A1AT-mCherry reporter cell line or just as the reporter cell line. 9
Importantly, EPO-eGFP and A1AT-mCherry are equally expressed from the same CMV 10 promoter, with their respective coding sequences separated by a sequence encoding a 11 P2A peptide ( Fig. 1A) . 12
We found that both EPO and A1AT are efficiently secreted from the reporter cell line 13 ( Fig. 1 B and C) and that disruption of ER-to-Golgi transport with Brefeldin A results in 14 intracellular accumulation of EPO and A1AT ( Fig. 1D ). Deletion of the ER cargo receptor 15 for A1AT, LMAN1, resulted in intracellular accumulation of A1AT, as expected, with no 16 effect on intracellular EPO (Fig. 1E ), ruling out a role for LMAN1 in EPO secretion. 17
These studies demonstrate that the machinery required for the efficient secretion of 18 EPO via the classical secretory pathway is intact in this cell line and establish the utility 19 of this cell line to identify modifiers of intracellular EPO levels. 20
A CRISPR/Cas9 loss-of-function screen identified SURF4 as a putative 21 regulator of intracellular EPO level 22
To identify proteins that affect EPO secretion, we mutagenized the EPO-eGFP/A1AT-1 mCherry reporter cell line with a CRISPR/Cas9 knockout library (hGeCKO-v2), which 2 delivers SpCas9, a puromycin resistance cassette, and a pooled collection of 123,411 3 single guide RNAs (sgRNAs) that include 6 sgRNAs targeting nearly every gene in the 4 human genome. Transduction of the library was performed at a low multiplicity of 5 infection (MOI ~0.3), such that most infected cells receive 1 sgRNA to mutate 1 gene in 6 the genome. Puromycin selection was applied from days 1-4 post-transduction. After an 7 additional 9 days, cells with normal mCherry but increased (top ~7%) or decreased 8 (bottom ~7%) eGFP fluorescence were isolated ( Fig. 2A ). This cell sorting strategy 9 allows the identification of genes that affect EPO but not A1AT levels, therefore reducing 10 the likelihood of identifying genes that affect global protein secretion. Integrated sgRNA 11 sequences were quantified by deep sequencing and analyzed for their enrichment in the 12 eGFP high compared to the eGFP low population. 13
This screen, performed in biological triplicates, identified that the sgRNA sequences 14 targeting only one gene, surfeit locus protein 4 (SURF4), are enriched in the eGFP high 15 population compared to the eGFP low population at an FDR <10% ( Fig. 2B ). Five out of 16 six sgRNAs targeting SURF4 were significantly enriched in the eGFP high population 17
( Fig. 2 C and D) . 18
SURF4 deletion results in intracellular accumulation and reduced secretion 19

of EPO 20
To validate the results of the screen, we targeted SURF4 with one sgRNA (sgRNA1) that 21 showed significant enrichment in the whole genome screen ( Fig. 2D ) and a second 22 sgRNA (sgRNA2) not included in the hGeCKO-v2 library. SURF4 mutagenesis with 23 sgRNA1 or sgRNA2 was highly efficient, resulting in insertions or deletions (indels) in 1 ~97% and 77% of alleles, respectively ( Fig. 3A ). Cells transduced with SURF4 sgRNA1 or 2 sgRNA2 exhibited increased intracellular accumulation of EPO-eGFP, with no effect on 3 A1AT-mCherry ( Fig. 3 B and C) . This finding was confirmed in 3 independent EPO-4 eGFP/A1AT-mCherry reporter cell clones ( Fig. 3D ), ruling out an artifact unique to the 5 clone used in the original screen. 6
To further confirm a direct effect of SURF4 deficiency on intracellular EPO 7 accumulation, we next generated 3 clonal reporter cell lines with confirmed frameshift 8 mutations of both SURF4 alleles, by transient expression of SURF4 sgRNA1 (SI 9
Appendix, Fig. S1 ). The increased intracellular EPO protein levels observed in SURF4 10 deleted cells was completely rescued by a lentivirus expressing wildtype SURF4 cDNA 11 ( Fig. 3 E and F) , ruling out an off-target effect shared by sgRNA1 and sgRNA2. Taken 12 together, these findings demonstrate that SURF4 disruption results in intracellular 13 accumulation of EPO. 14 To rule out an indirect effect on EPO-eGFP secretion resulting from an interaction 15 between eGFP and SURF4, we analyzed the dependence of FLAG-tagged EPO on SURF4 16 for secretion. We generated a wildtype and a SURF4 deficient HEK293 cell line 17 expressing FLAG-tagged EPO (EPO-FLAG) from a tetracycline-inducible promoter ( Fig.  18 4A). Following tetracycline administration, the intracellular EPO accumulation was 19 significantly more pronounced in SURF4-deficient compared to wildtype cells ( Fig. 4B) , 20 recapitulating the findings described above with EPO-eGFP and ruling out an indirect 21 effect due to the eGFP tag. 22 SURF4 localizes to the ER membrane (31-33) and functions as an ER cargo receptor, 1 suggesting that the increased accumulation of intracellular EPO in the setting of SURF4 2 deficiency is secondary to reduced EPO secretion. Consistent with this hypothesis, the 3 extracellular EPO-FLAG protein level was considerably lower in the conditioned media 4 of SURF4-deleted cells compared to wildtype cells ( Fig. 4 B and C) , as was the ratio of 5 extracellular to intracellular EPO-FLAG levels (Fig. 4D) . The latter findings observed in 6 SURF4-deficient cells were rescued by stable expression of SURF4 cDNA ( Fig. 4 B and 7 C). These results indicate that disruption of SURF4 results in a defect in EPO secretion. 8
SURF4 deletion results in accumulation of EPO in the ER 9
We next performed live cell fluorescent confocal microscopy to determine the 10 localization of accumulated EPO in the setting of SURF4 deletion. We co-transfected the 11 EPO-eGFP/A1AT-mCherry reporter construct ( Fig. 1A) with a vector expressing an ER 12 blue fluorescent marker (ERoxBFP) into wildtype or SURF4 deficient (SI Appendix, Fig.  13 S1) HEK293 cells. We quantified the degree of co-localization between EPO and 14
ERoxBFP (as well as A1AT and ERoxBFP, as control) by Pearson correlation coefficient 15 (PCC). SURF4 deficient cells exhibited an increased co-localization of EPO (but not 16 A1AT) with ERoxBFP compared to wildtype cells (PCC 0.7870 in SURF4 deleted cells 17 versus 0.2934 in wildtype cells, p<0.0001) ( Fig. 5 A and B) . 18
To confirm the ER accumulation of EPO upon SURF4 disruption, we tested the 19 glycosylation status of EPO in SURF4-deficient cells. EPO contains 3 N-glycosylation 20 sites. In the ER, N-linked high mannose oligosaccharides are added to EPO and further 21 modifications are made in the Golgi apparatus. The ER form of EPO is cleavable by 22
EndoH, but the post-ER form is not. Therefore, the ratio of EndoH cleaved to EndoH 23 uncleaved EPO will approximate the ratio of the amount of EPO in the ER versus the 1 amount of EPO in the Golgi apparatus or beyond. In SURF4 deficient cells, the ratio of 2 ER/post-ER form of EPO was significantly increased compared to that in wildtype cells 3 ( Fig. 5 C and D and SI Appendix, Fig. S2 ), an effect that was decreased by stable 4 expression of SURF4 cDNA ( Fig. 5 C and D) . Taken together, these results demonstrate 5 that SURF4 promotes the efficient ER exit and secretion of EPO. 6
SURF4 physically interacts with EPO 7
To determine if SURF4 binds to EPO, we tested for reciprocal co-immunoprecipitation 8 of SURF4-FLAG and EPO-GFP in HEK293T cells. An antibody against the FLAG 9 epitope co-immunoprecipitated EPO-eGFP but not the ER luminal resident protein 10 calnexin. Similarly, an antibody against GFP co-immunoprecipitated FLAG-SURF4 ( Fig.  11 5E). These results are consistent with a specific physical interaction between SURF4 and 12
EPO. 13
TPO shares significant sequence homology with EPO. To test if TPO, similarly to EPO, 14 depends on SURF4 for efficient secretion, we generated 2 independent clonal HEK293 15 cells stably expressing and efficiently secreting TPO-eGFP and A1AT-mCherry ( Fig. 6 A  16 and B). Like A1AT, TPO did not accumulate intracellularly upon SURF4 deletion ( Fig. 6  17 C and D). These findings demonstrate the specificity of SURF4 for promoting EPO 18 secretion and suggest that the SURF4/EPO interaction is mediated by one of the EPO 19 domains not present in TPO. 20
SURF4 promotes the secretion of endogenous EPO 21
The experiments described above were performed in a heterologous cell line 22 overexpressing EPO fused to either an eGFP or a FLAG tag. To test the impact of SURF4 23 deletion on the secretion of endogenous EPO, we transduced human HEP3B cells with 1 SURF4-targeting sgRNAs or control sgRNAs. As a positive control, a sgRNA targeting 2 EPO resulted in profound reduction of extracellular EPO level to almost an undetectable 3 (0.45% of control) level ( Fig. 7) . Disruption of SURF4 in HEP3B cells using 2 4 independent sgRNAs resulted in a significant reduction (51.22% of control) of 5 extracellular EPO levels compared to cells transduced with control sgRNAs (Fig 7) . 6
SURF4 overexpression promotes more efficient EPO secretion 7
We next determined if SURF4 overexpression promotes more efficient EPO secretion. 8
We generated a lentivirus expressing equal amounts of SURF4 and Katushka2S 9 (SURF4-p2A-Katushka2S, Fig. 8A ) and transduced it into HEK293 cells expressing 10 EPO-FLAG from a tetracycline inducible promoter. Cells with the highest (top 10%) and 11 lowest (bottom 10%) SURF4 expression, as determined by Katushka2 fluorescence, were 12 FACS sorted. Following tetracycline administration, EPO level was found to be 13 significantly increased in the conditioned media of cells overexpressing SURF4 14 compared to cells expressing low SURF4, with the reverse pattern observed 15 intracellularly ( Fig. 8 B- 
D). 16
To assess the impact of SURF4 overexpression on the secretion of EPO expressed from 17 its endogenous genomic locus, we performed the same experiment described above in 18 HEP3B cells. EPO level was increased in the conditioned media of cells expressing high 19 compared to low SURF4 levels ( Fig. 8E ). Taken together, these results demonstrate that 20 SURF4 overexpression promotes more efficient EPO secretion. 21
Discussion 1
In this report, we developed an unbiased genome-scale loss-of-function screen and 2 identified SURF4 as a regulator of intracellular EPO levels. Deletion of SURF4 resulted 3 in intracellular accumulation and extracellular depletion of EPO. Overexpression of 4 SURF4 resulted in the reversed pattern. Consistent with the reported localization of 5 SURF4 at the ER membrane (32, 34, 35), we found that disruption of SURF4 resulted in 6 accumulation of EPO in the ER, and that EPO and SURF4 physically interact. Taken 7 together, these results strongly suggest that SURF4 is the ER cargo receptor that 8 mediates the efficient secretion of EPO. 9
The screen described above was performed in a cell line with heterologous 10 overexpression of EPO under the control of a CMV promoter. Therefore, it was 11 important to examine if SURF4 facilitates the secretion of EPO when expressed at a 12 more physiological level. Accordingly, we deleted SURF4 in HEP3B cells which were 13 induced to express EPO from its endogenous genomic locus, and found that SURF4 also 14 promotes EPO secretion under these conditions. 15 SURF4 is the mammalian ortholog of yeast Erv29p. Erv29p facilitates packaging of pro-16 alpha-factor in COPII vesicles promoting their ER-to-Golgi transport (31, 36, 37). 17
Erv29p recycles back from Golgi-to-ER via recognition of its well-conserved di-lysine 18 sorting signal by the COPI coat (38). In mammalian cells, only a handful of cargos 19 (APOB, PCSK9, DSSP, AMLEX, and GH) have been shown to depend on SURF4 for 20 efficient secretion (32, 33, 39). However, a recent report demonstrated that mice with 21 germline deletion of Surf4 exhibit early embryonic lethality (40) similar to C. elegans 22 (33), suggesting the presence of one or more SURF4-dependent cargos with a critical 23 function during embryogenesis. Future studies aimed at identifying the repertoire of 1 cargos that depend on SURF4 for secretion are essential. 2 A recently published report suggested that the cargo proteins that depend on SURF4 for 3 secretion contain an N-terminal tripeptide 'ER-ESCAPE' motif (39). This motif is 4 exposed following removal of the leader sequences and is recognized by SURF4 (39). 5
However, an N-terminal 'ER-ESCAPE' motif with high SURF4 binding affinity is not 6 present in EPO. Additionally, we found that EPO, but not TPO, depends on SURF4 for 7 efficient secretion. However, TPO has an N-terminal motif with a better predicted 8 SURF4 binding affinity than EPO. These results suggest that the N-terminal 'ER-9
ESCAPE' motif may not be a generalizable determinant of SURF4 interaction for all 10 SURF4-dependent cargos. 11
Soluble cargos are exported from the ER via the passive "bulk flow" or the concentrative 12 "cargo capture" processes, with several lines of evidence supporting one route versus the 13 other(4). Though "bulk flow" and "cargo capture" are not mutually exclusive, this report 14 provides support for the "cargo capture" model of EPO secretion. However, it is 15 important to note that in our experimental conditions, ~50-70% of extracellular EPO is 16 reduced in the setting of SURF4-deficiency. Therefore, the secretion of the remaining 17 EPO depends on either bulk flow or one or more separate and unidentified receptors. 18
Recent developments in genome engineering using CRISPR/Cas9 technology have 19 dramatically enhanced the potential and efficacy of comprehensive, high throughput 20
genetic screens (41-55). Such strategies can be applied in vitro and in vivo to discover 21 novel biologic insights. Our screen was designed to focus on post-transcriptional 22 regulators of EPO by placing its expression under the control of a CMV promoter. 23
Screening strategies similar to the one employed in this manuscript and in a recently 1 published report (32) might help identify additional ER cargo receptors for other soluble 2 secreted proteins, and shed more light into the extent of the contribution of "cargo 3 capture" to recruitment of cargos into COPII vesicles. 4
Findings in this report may have important implications for erythropoiesis. EPO, the 5 master regulator of erythropoiesis, is produced by specialized peritubular fibroblasts in 6 the kidney. The transcriptional control of EPO via the hypoxia inducible factor pathway 7 has been well studied (28, 56-65) culminating in the development of prolyl hydroxylase 8 inhibitors, a class of compounds that increase EPO production at the transcriptional 9 level via activation of the hypoxia inducible factor (66-73). These drugs are currently in 10 clinical development, with several compounds in advanced phase 2 or 3 trials (74-78); 11 however, there are numerous potential concerns and adverse effects of these drugs, 12
including possible increased risks of malignancy and autoimmune disease (79-81). 13
Similar to the transcriptional control of EPO, the intracellular signal transduction 14 pathway downstream of the EPO receptor has also been well studied(82-84). In 15 contrast, much less is known about the molecular basis of EPO trafficking. Our findings 16
suggest that modulating SURF4 may be effective for the treatment of disorders of 17 erythropoeisis that are driven by aberrant EPO levels (85-90). Though a handful of 18 other cargos depend on SURF4 for their secretion (32, 33, 39), with additional cargos 19 likely remaining to be identified, targeting SURF4 exclusively in the EPO producing cells 20 might alter plasma EPO levels and therefore regulate erythropoiesis without affecting 21 other SURF4-dependent cargos that are expressed in other cells. Alternatively, an 22
inhibitor that specifically disrupts the SURF4-EPO interaction would also be expected to 23 have no effects on other cargos that bind SURF4. 24
Recombinant human EPO (rhEPO) is used clinically for the treatment of anemia due to 1 chronic kidney disease, chemotherapy, or ziduvidine. rhEPO is also used to reduce the 2 requirement of allogeneic red blood cell transfusion following certain elective surgeries. 3
Though the use of rhEPO is indicated in only a subset of the above clinical scenarios, the 4 rhEPO market size was valued at ~7.4 billion US dollars in 2016 (91). In this report, we 5 demonstrate that SURF4 overexpression results in enhanced EPO secretion. This 6 approach could be applied to increase the efficiency of rhEPO production, which might 7 translate into reduced costs of this drug. supplemented with 2mM L-glutamine (Gibco), 10% heat-inactivated fetal bovine serum 7 (Peak), and 1% penicillin-streptomycin (Gibco). All cells were grown in a humidified 8 37 o C incubator with 5% CO2. 9
Generation of the EPO-GFP A1AT-mCherry reporter cell line 10
The CMV-EPO-eGFP-p2A-A1AT-mCherry construct was assembled using the NEBuilder 11
HiFi DNA assembly cloning kit (NEB) using vector sequences derived from PCSK9-12 eGFP-p2A-A1AT-mCherry (32) and EPO cDNA obtained from Dharmacon. HEK293T 13 cells were transfected with CMV-EPO-eGFP-p2A-A1AT-mCherry using Fugene HD 14 transfection reagent (Promega). Transfected cells were selected with 350µg/mL 15 hygromycin (Invitrogen). Five weeks following hygromycin selection, single cells were 16 sorted into 96-well plates using a SY-3200 flow cytometer (Sony). Single cell clones 17 were expanded and analyzed for stable expression of EPO-eGFP and A1AT-mCherry 18 using a LSR Fortessa flow cytometer (BD Bioscience). 19
Generation of the TPO-GFP A1AT-mCherry reporter cell line 20
The TPO cDNA sequence was amplified from human liver RNA (de-identified tissue 21 sample obtained from the tissue procurement core, University of Michigan, IRB 22 #HUM00048303) and the CMV-TPO-eGFP-p2A-A1AT-mCherry construct was 1 generated and transfected into HEK293T cells as described in the paragraph above. 2
Single cell clones were sorted, expanded, and analyzed for stable expression of TPO-3 eGFP and A1AT-mCherry, as described above. 4
Expansion and lentiviral preparation of the pLentiCRISPRv2 library 5
The pLentiCRISPRv2 whole genome CRISPR library was obtained from Addgene 6 (Addgene #1000000048, a gift from Feng Zhang (41)), expanded by 16 electroporations 7 (8 for each half library) into Endura electrocompetent cells (Lucigen), and plated on 8 sixteen 24.5 cm bioassay plates (ThermoFisher Scientific). Following a 12-14 hour 9 incubation at 37C, colonies were harvested from agar plates, and pooled plasmids for 10 each half library were isolated separately by Maxipreps using an EndoFree Plasmid 11
Maxi Kit (Qiagen). To prepare the pooled lentiviral library, 11.3 ug of each half library 12 was co-transfected with 17 ug of psPAX2 (Addgene #12260, a gift from Didier Trono) 13 and 11.3 ug of pCMV-VSV-G (addgene #8454, a gift from Robert Weinberg (92)) using 14
Lipofectamine LTX with PLUS reagent (ThermoFisher Scientific) into each of six T225 15 tissue culture flasks (ThermoFisher Scientific) containing HEK293T cells at ~80-90% 16 confluency. Media was changed 24 hours post-transfection, and viral supernatant was 17 collected 12, 24, and 36 hours afterwards. Media containing viral supernatant was 18 centrifuged at 500 g for 5 min, pooled, aliquoted, snap-frozen in liquid nitrogen, and 19 stored at -80C. 20
CRISPR/Cas9 loss-of-function genome wide screen 21
For each independent screen, more than 142 million reporter cells were plated in 15-cm 22 tissue-culture dishes (Corning) at 30% confluency. Cells were transduced with the 23 lentiviral library (with 8ug/ml polybrene, Sigma) at a multiplicity of infection (MOI) of 1 ~0.3. Twenty-four hours post-viral transduction, puromycin selection (1 ug/ml, Sigma) 2 was applied for 4 days. Subsequently, cells were kept at a logarithmic phase of growth 3 and passaged every 2-3 days, maintaining more than 36 million cells in culture at all 4 times in order to preserve library depth. Fourteen-days post-transduction, ~80 million 5 cells were isolated from tissue culture dishes using trypsin 0.25% (Gibco), pelleted by Polymerase kit (Agilent biotechnologies). DNA was purified after each of the PCR 16 reactions using a QIAquick PCR purification kit (Qiagen). Following the 2 step PCR, 17
DNA was analyzed with a bioanalyzer (Agilent) and the sgRNA amplicons were 18 sequenced using a NextSeq 500 Sequencing System (Illumina). On average, 23.5 million 19 reads were generated for each sorted cell population of each screen. Overall, 98% of the 20 reads had a per sequence quality score (phred-based base quality score) of greater than 21 30. 104,331 sgRNA sequences were mapped and identified (along with the barcode 22 corresponding to each cell population of each replicate) using a custom Perl Script as 23 previously described (32). Enrichment at the sgRNA and gene levels was analyzed using 1 DESeq2 and MAGeCK, respectively (93, 94). 2 Disruption of candidate genes using CRISPR/Cas9 3 sgRNAs targeting several genes and several non-targeting sgRNAs (listed in SI 4
Appendix, Table S1 ) were cloned into the pLentiCRISPRv2 plasmid (Addgene:52961, a 5 gift from Feng Zhang (41) as previously described (42). pLentiCRISPR plasmids were 6 packaged into Lentivirus, using the same method described above. To disrupt genes in a 7 population of cells, cells were transduced with lentivirus at an MOI of ~0.3. 8
Subsequently, transduced cells were selected with puromycin and passaged for 10-14 9
days prior to FACS analysis. For all validation experiments, a minimum of 3 biologic 10 replicates were analyzed. 11
Generation of SURF4-deficient clonal cell lines 12
To generate clonal cell lines that are deficient for SURF4, a sgRNA targeting SURF4 13 exon 2 (SI Appendix, Table S1 ) was cloned into the PX459 plasmid (Addgene: 62988, a 14 gift from Feng Zhang) as previously described (95), and the construct was transiently 15 transfected into cells using Fugene HD transfection reagent (Promega). Twenty-four 16 hours post-transfection, puromycin (1ug/mL, Sigma) selection was applied for 3 days, 17 and subsequently, single cells were sorted into each well of three 96-well plates using 18 the SY-3200 flow cytometry instrument (Sony). Following expansion of the single cell 19 clones, genomic DNA was extracted with QuickExtract (Epicentre) and indels were 20 determined by amplification of the sgRNA target site by polymerase chain reaction 21
using Herculase II Fusion DNA Polymerase (Agilent biotechnologies) and Sanger 22 sequencing. Primers used for PCR and Sanger sequencing are listed in SI Appendix, 23 Table S1 . Three independent single cell clones with homozygous frameshift indels in 1 SURF4 were generated. 2
Flow Cytometry analysis 3
HEK293T cells were detached with 0.25% trypsin (Gibco), washed with PBS, collected 4 by centrifugation (350 g, 5 min, 4C), resuspended in cold PBS with 0.1% BSA and 10mM 5 HEPES (Invitrogen), filtered with 70 µm cell strainers, and analyzed by BD LSR 6
Fortessa (BD Bioscience). FlowJo (Tree Star) was used to calculate the mean 7 fluorescence intensity and for further analysis. 8
Brefeldin A treatment 9
HEK293 cells stably expressing EPO-eGFP and A1At-mCherry were incubated with 10 1ug/mL Brefeldin A (Biolegend) for 12 hr. Subsequently, cells were collected as 11 described above and analyzed by flow cytometry for intracellular accumulation of EPO-12 eGFP and A1AT-mCherry. 13
Western blots 14
To prepare cell lysates, cells were washed in PBS, suspended in RIPA buffer (Invitrogen) 15 supplemented with cOmplete protease inhibitor cocktail (Sigma), briefly sonicated, and 16 incubated for 30 minutes in the cold room with end-over-end rotation. Cell lysates were 17 cleared by centrifugation to remove cell debris (20,000 g, 30 min, 4C) and were 18 analyzed immediately or stored at -80C until analysis. Protein quantification was 19 performed using Pierce BCA protein assay kit (ThermoFisher Scientific) per 20 manufacturer's instruction. Lysates were boiled for 5 min at 95C with 4X Laemmli 21 sample buffer (Bio-Rad) supplemented with b-mercaptoethanol. Equal amounts of 22 proteins were loaded on either a 4-12% Bis-Tris gel or a 4-20% Tris-Glycine gel 1 (Invitrogen), and SDS gel electrophoresis was performed as previously described (96, 2 97). Proteins were then transferred onto a nitrocellulose membrane (Bio-Rad). 3
Following blocking in 5% (wt/vol) milk-Tris-buffered saline with Tween (TBST), 4 membranes were incubated with primary antibody at 4C overnight, washed 3 times in 5 TBST, probed with peroxidase-coupled secondary antibodies, washed again 3 times in 6 TBST, and developed with SuperSignal West Pico Plus (ThermoFisher Scientific). For 7 HRP-conjugated primary antibodies, nitrocellulose membranes were incubated with 8 these antibodies and immediately developed following 3 TBST washes. Densitometry 9 was performed with ImageJ. To test for the secretion efficiency of various cargo 10 proteins, cells were seeded at equal densities in 6-well plates or 10-cm plates, and 11 conditioned media was collected at different time points, cleared by centrifugation (500 12 g, 5 min, 4C), and analyzed immediately (by western blot) as described above, or stored 13 at -80C until analysis. 14
Antibodies 15
The following antibodies were used for immunoblotting: Anti-GFP (Abcam, ab290), Laboratories, 111-035-003). 21
Tetracycline induced EPO-FLAG expression 22
The coding sequence of EPO with a C-terminal Flag was cloned into pDEST-pcDNA5-1
BirA-FLAG (Invitrogen) using NEBuilder HiFi DNA assembly cloning kit (NEB). 2 Wildtype, SURF4-deficient (with homozygous frameshift SURF4 indels), or SURF4-3 rescue (with homozygous frameshift SURF4 indels but with stable expression of SURF4 4 cDNA) Flp-In T-REx HEK293 cells with tetracycline-inducible expression of EPO-FLAG 5 were generated as previously described (98). To induce the expression of EPO-FLAG, 6 tetracycline (1 ug/mL) was added to the media. Cells and media were collected prior to 7 the addition of tetracycline and 12-and 24-hours following tetracycline. Intracellular 8 and extra-cellular EPO levels were analyzed by western blot as described above. 9
Endoglycosidase H (EndoH) assay 10
HEK293T cells that are either wild-type, SURF4-deficient, or SURF4-rescue (defined in 11 the paragraph above) were transfected with a plasmid expressing EPO-eGFP. Thirty-six 12 hours post-transfection, total cell lysates were prepared, and protein quantification was 13 performed, both as described above. Lysates were incubated with denaturing buffer 14 (NEB) 95 o C for 10 minutes and equal amounts of lysates (180 ug) were treated with 15 either 1uL of EndoH (NEB), PNGase F (NEB), or DMSO as control for 1 hour (37 o C). 16
Subsequently, Laemmli buffer (Bio-RaD) was added and the samples were boiled (95 o C) 17
for 5 min. Samples were loaded on a 4-12% Bis-Tris Gel (Invitrogen) and Western blot 18 was performed as described above. This experiment was performed in biologic 19
triplicates. 20
Live cell confocal fluorescent microscopy 21
Wild-type or SURF4-deficient HEK293T cells that stably express EPO-eGFP and A1AT-22 mCherry were transfected with a plasmid expressing ERoxBFP (Addgene: 68126, a gift 23 from Erik Snapp (99)). Twenty-four hours post-transfection, cells were seeded on Lab-1
Tek Chambered Coverglass (ThermoFisher). Fluorescent images were captured on a 2 Nikon A2 confocal microscope. To quantify colocalization between 2 proteins, Pearson 3 correlation coefficient was calculated using the Nikon Elements software. This 4 experiment was performed and analyzed by an investigator blinded to the genotype of 5 the cells. 6
Co-immunoprecipitation 7
Flp-In T-Rex 293 cells that are either wild-type, SURF4-deficient, or SURF4-rescue 8 (defined above) were transfected with CMV-EPO-eGFP-p2A-A1AT-mCherry using 9
Fugene HD transfection reagent (Promega). Twenty-four hours post-transfection, cells 10 were washed with PBS and incubated in PBS containing 2 mM dithiobis (succinimidyl 11 propionate) (Pierce) for 30 min at room temperature. Subsequently, 20 mM Tris-HCL 12 (pH 7.5) was added to quench the reaction. Cells were then washed twice in PBS and cell 13 lysis was performed with the following lysis buffer (100 mM tris, 10% glycerol, 1% NP-14 40, 130 mM NaCl, 5 mM MgCl2, 1 mM NaF and 1mM EDTA, supplemented with 15 cOmplete protease inhibitor cocktail pH 7.5). Cell lysates were collected as described 16 above and incubated overnight at 4C with either anti-FLAG M2 magnetic beads (Sigma) 17 or GFP-Trap beads (ChromoTek). Following 5 washes with lysis buffer, proteins were 18 eluted from the beads via incubation with 2X Laemmli sample buffer containing b-19 mercaptoethanol for 15 minutes at room temperature. 20
Generation of cell lines expressing low or high SURF4 levels 21
A construct expressing SURF4 and the Katushka2S fluorescent marker (PGK-SURF4-22 p2A-Katushka2S) was assembled with the NEBuilder HiFi DNA assembly cloning kit 23 (NEB) using vector sequence derived from LV1-5 (Addgene #68411) and cDNAs of 1 SURF4 and Katushka2S (a gift from Gary Luker(100)). The construct was packaged into 2 lentivirus as described above and transduced at MOI of ~1 into Flp-In T-REx 293 or 3 HEP3B cells. Transduced cells were selected with puromycin and passaged for 14 days 4 prior to FACS sorting. Cells with top and bottom 10% Katushka2S fluorescence we 5 sorted. 6
Generation of SURF4-deficient HEP3B cells 7
Wild-type HEP3B cells were transduced with lentiviral sgRNA targeting SURF4, control 8 sgRNA (combination of non-targeting sgRNAs and sgRNAs targeting genes that do not 9 affect EPO: BCL11A, MPL, SERPINA1), or sgRNA targeting EPO as a positive control. 10
Cells were selected with puromycin and passaged for at least two weeks prior to further 11 analysis. EPO levels in the conditioned media were compared between SURF4 deleted 12 cells and control cells, correcting for the total cell number at the time of EPO 13 measurement. Genomic DNA was extracted from HEP3B cells using QuickExtract 14 (Epicentre). 15
EPO ELISA 16
Equal numbers of cells were seeded in 6-well or 24-well plates. For HEP3B cells, EPO 17 production was stimulated with CoCl2 (75 µM, Sigma) for 24 hours and conditioned 18 media was collected and cleared by centrifugation (500 g, 5 min, 4C). For Flp-In T-Rex 19
HEK293 cells with tetracycline-inducible expression of EPO-FLAG, tetracycline 20
(1µg/mL) was added for 12 hours and conditioned media was collected, cleared by 21 centrifugation (500 g, 5 min, 4C) and diluted 1:500. EPO level was measured in the 22 conditioned media using the LEGEND MAX Human Erythropoietin ELISA kit 1 (Biolegend), according to manufacturer's instructions. The authors declare no competing interests. 9 enrichment score was calculated for every gene using MAGeCK (see methods). Each 20 gene is represented by a bubble, the size of which is proportional to number of sgRNAs 21 with significant enrichment in the eGFP high population. SURF4 has the highest 22
Figure Legends
MAGeCK enrichment score and is the only gene for which the false discovery rate (FDR) 23 is <10%. NT: non-targeting. (C) Normalized abundance of SURF4-targeting sgRNAs in 24 the eGFP high and eGFP low populations. Abundance score calculated from 3 biological 25
replicates, using DEseq (see methods). SURF4 sgRNAs are highlighted in orange. (D) 26
Normalized counts for the 6 SURF4 targeting sgRNAs included in the library, for all 3 27 biological replicates. p-values were calculated using MAGeCK. transduced with SURF4-targeting sgRNAs (n=29). Results were normalized to mean 30 flourescence intensity of cells transduced with non-targeting sgRNAs. As a positive 31 control, the same experiment was performed in parallel in reporter cell lines expressing 32
EPO-eGFP and A1AT-mCherry (n=48). **** p<0.0001, ns=non-significant. 33 34 Fig. 7 . SURF4 deletion in HEP3B cells results in reduced extracellular 35 secretion of EPO expressed from its endogenous genomic locus. HEP3B cells 36
were transduced with lentivirus expressing SURF4-targeting sgRNAs, control sgRNAs, 37
or EPO-targeting sgRNA as a positive control. EPO expression from its endogenous 38 regulatory elements was subsequently induced with CoCl2 and measured in the 39 conditioned media by ELISA and normalized to the total number of cells. ** p <0.01, 40 **** p<0.0001. Katushka2S fluorescence were FACS sorted, corresponding to cells overexpressing 47
